US8592443B2 - Use of 4 cyclopropylmethoxy-N-(3,5 dichloro-1 oxido-pyridin-4 yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas - Google Patents

Use of 4 cyclopropylmethoxy-N-(3,5 dichloro-1 oxido-pyridin-4 yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas Download PDF

Info

Publication number
US8592443B2
US8592443B2 US12/573,316 US57331609A US8592443B2 US 8592443 B2 US8592443 B2 US 8592443B2 US 57331609 A US57331609 A US 57331609A US 8592443 B2 US8592443 B2 US 8592443B2
Authority
US
United States
Prior art keywords
carboxamide
dichloro
methoxy
pyridine
cyclopropylmethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US12/573,316
Other versions
US20100137370A1 (en
Inventor
Philippe DELAY-GOYET
Badia Ferzaz
Jocelyne LOLIVIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of US20100137370A1 publication Critical patent/US20100137370A1/en
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FERZAZ, BADIA, LOLIVIER, JOCELYNE, DELAY-GOYET, PHILIPPE
Assigned to SANOFI reassignment SANOFI CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SANOFI-AVENTIS
Application granted granted Critical
Publication of US8592443B2 publication Critical patent/US8592443B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide, in the form of a hydrate, of a solvate, of a base or of an addition salt with an acid, for the preparation of a medicament for use in the treatment of spinal cord traumas.
  • PDE 4 phospho-diesterases 4
  • studies have shown, in animals, that a possible approach is the administration of compounds which inhibit phospho-diesterases 4 (PDE 4), such as, for example, rolipram.
  • PDE 4 phospho-diesterases 4
  • clinical studies have shown that this compound, and also other inhibitors of PDE 4, induce emetic effects which do not allow it to be used in therapy.
  • a first subject of the invention therefore relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the preparation of a medicament for use in the treatment of spinal cord traumas.
  • the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide can be carried out with the latter in the form of a base or of an addition salt with an acid.
  • salts that can be used in the context of the invention can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for the purification or the isolation of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide are also part of the invention.
  • spinal cord trauma is intended to mean acute or chronic pathologies which have an external origin and which destroy the spinal tract and/or neurons, and which occur, for example, during a fall, an impact, crushing or a road accident.
  • a second subject of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide as active ingredient and one or more pharmaceutically acceptable excipients.
  • composition used according to the invention comprises an effective dose of the active ingredient.
  • the daily doses of active ingredient that can be used according to the invention are from 0.001 to 10 mg/day.
  • the dosage appropriate for each patient is determined by the physician according to the method of administration and the age, weight and response of said patient.
  • the doses depend on the desired effect, on the duration of treatment and on the route of administration used.
  • excipients are chosen, according to the pharmaceutical form and the method of administration desired, from the usual excipients which are known to those skilled in the art.
  • composition may be administered orally, parenterally (including intrathecally) or rectally.
  • Suitable unit administration forms comprise oral administration forms, such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular, intravenous or intrathecal administration forms, rectal administration forms, and implants.
  • oral administration forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions
  • sublingual, buccal, intratracheal, intraocular and intranasal administration forms forms for administration by inhalation
  • topical, transdermal, subcutaneous, intramuscular, intravenous or intrathecal administration forms rectal administration forms, and implants.
  • the active ingredients according to the invention may be used in creams, gels, ointments or lotions.
  • compositions When a composition is prepared in tablet form, the active ingredient is mixed with one or more pharmaceutical excipients, such as gelatin, starch, lactose, magnesium stearate, talc, silica, gum arabic, mannitol, microcrystalline cellulose, hypromellose, or the like.
  • pharmaceutical excipients such as gelatin, starch, lactose, magnesium stearate, talc, silica, gum arabic, mannitol, microcrystalline cellulose, hypromellose, or the like.
  • the tablets may be coated with sucrose, with a cellulosic derivative or with other substances suitable for coating.
  • the tablets may be produced by various techniques, such as direct compression, dry or wet granulation, or hot melt.
  • a pharmaceutical composition in the form of a gel capsule by mixing the active ingredient with a diluent and transferring the mixture obtained into soft or hard gel capsules.
  • aqueous suspensions for parenteral administration, use is made of aqueous suspensions, isotonic saline solutions or sterile injectable solutions which contain pharmacologically compatible agents, for example propylene glycol or butylene glycol.
  • pharmacologically compatible agents for example propylene glycol or butylene glycol.
  • a unit administration form of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in tablet form comprises the following ingredients:
  • the Beam Balance test consists in placing the mouse at the end of a horizontal beam 30 cm long and 1.5 cm wide, raised 20 cm above the ground. The time required for the mouse to reach the opposite end of the beam is measured. The test is stopped after 12 seconds. If the animal falls or does not accomplish the test, the maximum time is noted.
  • mice are subjected to a pre-learning phase which allows them to become familiar with the evaluation test and allows them to reach an optimal and identical level of performance.
  • the animals are subsequently divided up into three groups, and then a trauma is induced in a controlled manner in two of the three groups of mice before the beginning of the test phase.
  • This trauma consists of a lesion of the spinal cord located at the level of the thoracic vertebra Th8.
  • the lesion is generated by 3 successive cycles of freezing-thawing by applying liquid nitrogen.
  • Table 1 shows that the traumatized animals to which 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide was administered curatively (group 3) reached the end of the balance beam more rapidly than the traumatized animals to which this compound was not administered (group 2).
  • Example 2 An experiment similar to that of Example 1 was carried out by administering ((4R)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidine-2-one) to 34-week-old OF1 mice (Charles River, France) weighing 12 to 14 g, in the treatment of spinal cord traumas.
  • mice were tested in the beam balance test, according to operating conditions identical to those described above.
  • mice The results obtained for each group of mice are expressed as percentage (%) deficiency of motor functions in the traumatized mice compared with the non-traumatized mice:
  • % deficiency of group ( c ) [(mean of the travel time of group C ) ⁇ (mean of the travel time of group A )]/[(mean of the travel time of group B ) ⁇ (mean of the travel time of group A )]
  • group A non-traumatized animals
  • group B traumatized animals treated with the carrier
  • group C traumatized animals treated with (R)-( ⁇ ) -Rolipram
  • a value greater than 100% indicates that the group of mice evaluated took, on average, more time to travel the distance than that taken, on average, by the group of traumatized mice treated with the vehicle.
  • the animals treated with 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide exhibit a degree of motor function deficiency which is less than that of the animals treated with (R)-( ⁇ )-Rolipram.
  • the emetic capacity of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide was evaluated in the ferret. Two groups of ferrets were used, the first being given the carrier (PEG 200) and the second being given 4-cyclopropyl-methoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in solution in the carrier (PEG 200), by oral gavage, at doses of 0.05 mg/kg and 0.1 mg/kg. The animals were observed continually for the 2 hours following administration and then every hour up to 6 hours after administration. The clinical signs (in particular retching and vomiting) were noted.
  • the emetic capacity of (R)-( ⁇ )-Rolipram was evaluated in the ferret. Two groups of ferrets were used, the first receiving the carrier (PEG200) and the second receiving 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in solution in the carrier (PEG200), by oral gavage, at doses of 0.05 mg/kg and 0.1 mg/kg. The animals were observed continually for the 2 hours following administration and then every hour up to 6 hours after administration. The clinical signs were noted.
  • 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide is of use in the preparation of a medicament for the treatment of nervous system traumas, in particular spinal cord traumas, such as, for example, traumas occurring during a fall, an impact or a car accident, or cerebral traumas, while at the same time avoiding possible emetic effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide, in the form of a hydrate, of a solvate, of a base or of an addition salt with an acid, for the preparation of a medicament for use in the treatment of spinal cord traumas.

Description

This application is a Continuation of International Application No. PCT/FR2008/000533, filed Apr. 16, 2008, which is incorporated herein by reference in its entirety.
The present invention relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide, in the form of a hydrate, of a solvate, of a base or of an addition salt with an acid, for the preparation of a medicament for use in the treatment of spinal cord traumas.
4-Cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide, alternatively called N-(3,5-dichloro-1-oxido-4-pyridinio)-4-cyclopropylmethoxy-5-methoxypyridine-2-carboxamide, is known to be part of the composition of medicaments for use in the treatment of various pathologies, including in particular inflammations of the joints, arthritis and rheumatoid arthritis. This compound, in hemihydrate form, is described, for example, in document WO 95/04045 (compound referenced FR).
There exists a need to find medicaments for treating patients suffering from spinal cord traumas. Studies have shown, in animals, that a possible approach is the administration of compounds which inhibit phospho-diesterases 4 (PDE 4), such as, for example, rolipram. However, clinical studies have shown that this compound, and also other inhibitors of PDE 4, induce emetic effects which do not allow it to be used in therapy.
It has now been found that 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide can be used in the treatment of spinal cord traumas while at the same time avoiding the emetic effects at therapeutically acceptable doses.
A first subject of the invention therefore relates to the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the preparation of a medicament for use in the treatment of spinal cord traumas.
According to one embodiment of the invention, the use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide can be carried out with the latter in the form of a base or of an addition salt with an acid.
The salts that can be used in the context of the invention can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for the purification or the isolation of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide are also part of the invention.
The use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide according to the invention can also be carried out with the latter in the form of a hydrate or of a solvate. The term “hydrate or solvate” is intended to mean the association or the combination of one or more molecules of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide with one or more molecules of water or of solvent.
For the purpose of the present invention, the term “spinal cord trauma” is intended to mean acute or chronic pathologies which have an external origin and which destroy the spinal tract and/or neurons, and which occur, for example, during a fall, an impact, crushing or a road accident.
A second subject of the invention relates to a pharmaceutical composition comprising 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide as active ingredient and one or more pharmaceutically acceptable excipients.
The composition used according to the invention comprises an effective dose of the active ingredient.
For example, the daily doses of active ingredient that can be used according to the invention are from 0.001 to 10 mg/day.
According to the usual practice, the dosage appropriate for each patient is determined by the physician according to the method of administration and the age, weight and response of said patient.
The doses depend on the desired effect, on the duration of treatment and on the route of administration used.
There may be specific cases where higher or lower dosages are appropriate. Such dosages do not depart from the context of the invention.
The excipients are chosen, according to the pharmaceutical form and the method of administration desired, from the usual excipients which are known to those skilled in the art.
The composition may be administered orally, parenterally (including intrathecally) or rectally.
Suitable unit administration forms comprise oral administration forms, such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular, intravenous or intrathecal administration forms, rectal administration forms, and implants. For topical application, the active ingredients according to the invention may be used in creams, gels, ointments or lotions.
When a composition is prepared in tablet form, the active ingredient is mixed with one or more pharmaceutical excipients, such as gelatin, starch, lactose, magnesium stearate, talc, silica, gum arabic, mannitol, microcrystalline cellulose, hypromellose, or the like.
The tablets may be coated with sucrose, with a cellulosic derivative or with other substances suitable for coating. The tablets may be produced by various techniques, such as direct compression, dry or wet granulation, or hot melt.
It is also possible to obtain a pharmaceutical composition in the form of a gel capsule by mixing the active ingredient with a diluent and transferring the mixture obtained into soft or hard gel capsules.
For parenteral administration, use is made of aqueous suspensions, isotonic saline solutions or sterile injectable solutions which contain pharmacologically compatible agents, for example propylene glycol or butylene glycol.
By way of example, a unit administration form of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in tablet form comprises the following ingredients:
4-Cyclopropylmethoxy-N-(3,5- 1 mg
dichloro-1-oxidopyridin-4-yl)-
5-(methoxy)pyridine-2-carboxamide
Mannitol 224 mg
Sodium croscarmellose 5 mg
Maize starch 15 mg
Hydroxypropylmethylcellulose 2 mg
Magnesium stearate 3 mg
The effects of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide used according to the invention were evaluated in a model of spinal trauma in the mouse using the beam balance test (P. Barnéoud, NeuroReport 1997, 8, 2861-2865).
EXAMPLE 1 Evaluation of the effectiveness of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of spinal cord traumas:
The Beam Balance test consists in placing the mouse at the end of a horizontal beam 30 cm long and 1.5 cm wide, raised 20 cm above the ground. The time required for the mouse to reach the opposite end of the beam is measured. The test is stopped after 12 seconds. If the animal falls or does not accomplish the test, the maximum time is noted.
34-week-old female OF1 mice (Iffa Credo Lyon, France) weighing 12 to 14 g are placed in experimental cages (32×21×14 cm) provided with an endless supply of food and water, at the controlled temperature of 22±1° C.
An experiment using the Beam Balance test is carried out in order to evaluate the effectiveness of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of spinal cord trauma.
The mice are subjected to a pre-learning phase which allows them to become familiar with the evaluation test and allows them to reach an optimal and identical level of performance.
The animals are subsequently divided up into three groups, and then a trauma is induced in a controlled manner in two of the three groups of mice before the beginning of the test phase.
This trauma consists of a lesion of the spinal cord located at the level of the thoracic vertebra Th8. The lesion is generated by 3 successive cycles of freezing-thawing by applying liquid nitrogen.
The functional consequences of the trauma are then measured at days 2, 7, 14 and 21 and also at day 28.
The following groups were formed:
    • Group 1 (no trauma) is composed of control animals which are not subjected to any trauma.
    • Group 2 (trauma alone) is composed of traumatized animals to which one dose per day of carrier (methyl-cellulose (MC) (0.6%) +tween-80 (0.5%) in water) is administered.
    • Group 3 (trauma+active ingredient 0.01 mg/kg at +4 hours) receives a solution containing 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide (0.01 mg/kg) in the carrier (MC (0.6%)+tween-80 (0.5%) in water), orally, 4 hours after the lesion, and then daily, orally, for 4 weeks after the trauma.
The results obtained for each group of mice are reported in Table 1:
TABLE 1
Results of the balance beam test for groups 1 to 3
Results (seconds)
D = 0
Groups D − 4 Trauma D + 2 D + 7 D + 14 D + 21 D + 28
1 (no 3.95 No 3.52 3.77 3.25 2.99 2.92
trauma)
2 (trauma 3.67 Yes 12.11 10.60 9.58 8.33 8.11
alone)
3 (trauma + 3.93 Yes 10.71 8.67 6.35 6.17 5.18
active
ingredient
at +4 h)
Table 1 shows that the traumatized animals to which 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide was administered curatively (group 3) reached the end of the balance beam more rapidly than the traumatized animals to which this compound was not administered (group 2).
Overall, these experiments show that the traumatized animals to which 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide was administered show a better re-establishment in terms of motor functions than the non-treated traumatized animals. The results are similar when the invention is administered preventively, i.e. prior to the trauma.
EXAMPLE 2 Evaluation of the effectiveness of ((4R)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidine-2-one) in the treatment of spinal cord traumas:
An experiment similar to that of Example 1 was carried out by administering ((4R)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidine-2-one) to 34-week-old OF1 mice (Charles River, France) weighing 12 to 14 g, in the treatment of spinal cord traumas.
((4R)-4-[3-(Cyclopentyloxy)-4-methoxyphenyl]-pyrrolidine-2-one), also called (R)-(−)-Rolipram, is in particular described in document U.S. Pat. No. 4,193,926.
The mice were tested in the beam balance test, according to operating conditions identical to those described above.
The following groups were formed:
    • Group A (no trauma) is composed of control animals which are not subjected to any trauma.
    • Group B (trauma alone) is composed of traumatized animals to which one dose per day of carrier (2% PEG 200) is administered.
    • Group C (trauma+active ingredient 0.03 mg/kg at +4 hours) receives a solution containing (R)-(−)-Rolipram (0.03 mg/kg) in the carrier (2% PEG 200), orally, 4 hours and 6 hours after the lesion, and then daily, orally, for 4 weeks after the trauma.
The results obtained for each group of mice are expressed as percentage (%) deficiency of motor functions in the traumatized mice compared with the non-traumatized mice:
To do this, the difference in time taken between the group of mice tested to which (R)-(−)-Rolipram was administered (group C) and the group of non-traumatized mice (group A) is measured and expressed as a percentage relative to the difference in time taken between the traumatized mice to which one dose per day of carrier was administered (group B) and the time taken by the non-traumatized mice (group A). This ratio therefore gives the percentage deficiency in motor functions of the traumatized mice compared with the non-traumatized mice.
This calculation of the percentage deficiency of the mice tested is performed according to the following formula:
% deficiency of group (c)=[(mean of the travel time of group C)−(mean of the travel time of group A)]/[(mean of the travel time of group B)−(mean of the travel time of group A)]
with:
group A: non-traumatized animals
group B: traumatized animals treated with the carrier
group C: traumatized animals treated with (R)-(−) -Rolipram
The higher the percentage expressed, the greater the motor function deficiency observed. Thus, a result of 100% (one hundred percent) corresponds to a group of traumatized mice on which no therapeutic effect is observed.
A value greater than 100% indicates that the group of mice evaluated took, on average, more time to travel the distance than that taken, on average, by the group of traumatized mice treated with the vehicle.
The results obtained for each group of mice are reported in Table 2:
TABLE 2
Results on the balance beam test for groups A to C:
Travel time (% motor function deficiency)
D = 0
Groups Trauma D + 2 D + 7 D + 14 D + 21 D + 28 Mean
A: (no No 0 0 0 0 0 0
trauma)
B: (trauma Yes 100 100 100 100 100 100
alone)
C: (trauma + Yes 110 67 48 122 108 91
(R)-(−)-
Rolipram
(0.03 mg/kg
po at +4 h))
These experiments show that the traumatized animals treated with (R)-(−)-Rolipram, even at administered doses 3 times greater than the administered doses of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide, exhibit a motor function deficiency which is greater than that of the animals treated with 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide.
By way of comparison, the values obtained for the traumatized mice to which 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide was administered (group 3 of Table 1) are reported in Table 3 in the form of percentage motor function deficiency:
TABLE 3
Comparison of the results obtained for groups of mice 3 and C
Travel time (% deficiency)
D = 0
Groups Trauma D + 2 D + 7 D + 14 D + 21 D + 28 Mean
C: (trauma + Yes 110 67 48 122 108 91
(R)-(−)-
Rolipram
(0.03 mg/kg
po at +4 h))
3: (trauma + Yes 84 72 49 60 44 62
compound of
the invention
(0.01 mg/kg
po at +4 h))
Group C: traumatized animals treated with (R)-(−)-Rolipram.
Group 3: traumatized animals treated with 4-cyclo-propylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide.
The animals treated with 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide exhibit a degree of motor function deficiency which is less than that of the animals treated with (R)-(−)-Rolipram.
EXAMPLE 3 Evaluation of the emetic effects of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide
The emetic capacity of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide was evaluated in the ferret. Two groups of ferrets were used, the first being given the carrier (PEG 200) and the second being given 4-cyclopropyl-methoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in solution in the carrier (PEG 200), by oral gavage, at doses of 0.05 mg/kg and 0.1 mg/kg. The animals were observed continually for the 2 hours following administration and then every hour up to 6 hours after administration. The clinical signs (in particular retching and vomiting) were noted.
When administered at 0.1 mg/kg, 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide induces no retching or vomiting in the 5 ferrets treated.
These results show that the administration of a therapeutic dose of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for treating spinal cord traumas does not cause any emetic effect.
EXAMPLE 4 Evaluation of the emetic effects of (R)-(−)-Rolipram (((4R)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidine-2-one))
The emetic capacity of (R)-(−)-Rolipram was evaluated in the ferret. Two groups of ferrets were used, the first receiving the carrier (PEG200) and the second receiving 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in solution in the carrier (PEG200), by oral gavage, at doses of 0.05 mg/kg and 0.1 mg/kg. The animals were observed continually for the 2 hours following administration and then every hour up to 6 hours after administration. The clinical signs were noted.
When administered at 0.05 mg/kg and 0.1 mg/kg, (R)-(−)-Rolipram induces vomiting in the ferrets treated.
The results of Examples 3 and 4 show that the administration of a therapeutic dose of (R)-(−)-Rolipram causes emetic effects.
Thus, 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide is of use in the preparation of a medicament for the treatment of nervous system traumas, in particular spinal cord traumas, such as, for example, traumas occurring during a fall, an impact or a car accident, or cerebral traumas, while at the same time avoiding possible emetic effects.

Claims (2)

We claim:
1. A method for treating spinal cord trauma comprising administering to a patient in need thereof a pharmaceutically effective amount of 4- cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy) pyridine-2- carboxamide, or a hemihydrate, or an addition salt with an acid thereof, wherein the treatment does not cause emetic effect or induce retching or vomiting to the patient.
2. A method for treating spinal cord trauma comprising administering to a patient in need thereof a pharmaceutically effective amount of 4- cyclopropylmethoxy -N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide, wherein the treatment does not cause emetic effect or induce retching or vomiting to the patient.
US12/573,316 2007-04-19 2009-10-05 Use of 4 cyclopropylmethoxy-N-(3,5 dichloro-1 oxido-pyridin-4 yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas Expired - Fee Related US8592443B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0702851 2007-04-19
FR0702851A FR2915098B1 (en) 2007-04-19 2007-04-19 USE OF 4-CYCLOPROPYLMETHOXY-N- (3,5-DICHLORO-1-OXYDO-PYRIDIN-4-YL) -5- (METHOXY) PYRIDINE-2-CARBOXAMIDE FOR THE TREATMENT OF TRAUMATISMS OF SPINAL CORD
PCT/FR2008/000533 WO2008145840A2 (en) 2007-04-19 2008-04-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000533 Continuation WO2008145840A2 (en) 2007-04-19 2008-04-16 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas

Publications (2)

Publication Number Publication Date
US20100137370A1 US20100137370A1 (en) 2010-06-03
US8592443B2 true US8592443B2 (en) 2013-11-26

Family

ID=38779706

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/573,316 Expired - Fee Related US8592443B2 (en) 2007-04-19 2009-10-05 Use of 4 cyclopropylmethoxy-N-(3,5 dichloro-1 oxido-pyridin-4 yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas

Country Status (32)

Country Link
US (1) US8592443B2 (en)
EP (1) EP2150253B1 (en)
JP (1) JP5386477B2 (en)
KR (1) KR101470043B1 (en)
CN (1) CN101674829B (en)
AR (1) AR066106A1 (en)
AT (1) ATE503481T1 (en)
AU (1) AU2008257321B2 (en)
BR (1) BRPI0810446A2 (en)
CA (1) CA2684172C (en)
CL (1) CL2008001134A1 (en)
CY (1) CY1111779T1 (en)
DE (1) DE602008005873D1 (en)
DK (1) DK2150253T3 (en)
EA (1) EA015355B1 (en)
ES (1) ES2363056T3 (en)
FR (1) FR2915098B1 (en)
HR (1) HRP20110459T1 (en)
IL (1) IL201451A (en)
JO (1) JO2662B1 (en)
MA (1) MA31369B1 (en)
ME (1) ME00934B (en)
MX (1) MX2009011285A (en)
MY (1) MY146657A (en)
NZ (1) NZ580483A (en)
PA (1) PA8776601A1 (en)
PL (1) PL2150253T3 (en)
PT (1) PT2150253E (en)
SI (1) SI2150253T1 (en)
TW (1) TWI411435B (en)
UY (1) UY31033A1 (en)
WO (1) WO2008145840A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393236B2 (en) 2007-04-19 2016-07-19 Sanofi Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxido-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of cranial traumas

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014083107A1 (en) * 2012-11-28 2014-06-05 Sanofi METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
CA2892151A1 (en) * 2012-11-28 2014-06-05 Sanofi Process for preparing 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide
US20220226302A1 (en) 2021-01-20 2022-07-21 Altos Neuroscience, Inc. Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions
WO2025079694A1 (en) * 2023-10-12 2025-04-17 株式会社 メドレックス Percutaneous absorption composition

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
WO1995004045A1 (en) 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
WO1995020578A1 (en) 1994-01-26 1995-08-03 Rhone-Poulenc Rorer Limited SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS
WO1996031476A1 (en) 1995-04-07 1996-10-10 Rhone-Poulenc Rorer Limited Aromatic hydroxyethers
WO2000015116A1 (en) 1998-09-10 2000-03-23 General Surgical Innovations, Inc. Direct vision subcutaneous tissue retractor
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
WO2001047915A1 (en) 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
WO2002069905A2 (en) 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2004005258A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
WO2004067006A1 (en) 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
GB2406856A (en) 2003-10-07 2005-04-13 Renovis Inc Novel amide compounds as ion channel ligands and uses thereof
WO2006135828A2 (en) 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
US7045660B2 (en) 1993-07-28 2006-05-16 Aventis Pharma Limited Compounds as PDE IV and TNF-inhibitors
WO1995004045A1 (en) 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
US8129537B2 (en) 1993-07-28 2012-03-06 Rhone-Poulenc Rorer Limited Compounds as PDE IV and TNF inhibitors
US7652144B2 (en) 1993-07-28 2010-01-26 Aventis Pharma Limited Compounds as PDE IV and TNF inhibitors
US6472412B1 (en) * 1993-07-28 2002-10-29 Aventis Pharma Limited Compounds as PDE IV and TNF inhibitors
WO1995020578A1 (en) 1994-01-26 1995-08-03 Rhone-Poulenc Rorer Limited SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS
WO1996031476A1 (en) 1995-04-07 1996-10-10 Rhone-Poulenc Rorer Limited Aromatic hydroxyethers
WO2000015116A1 (en) 1998-09-10 2000-03-23 General Surgical Innovations, Inc. Direct vision subcutaneous tissue retractor
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
JP2003519139A (en) 1999-12-23 2003-06-17 アイコス コーポレイション Cyclic AMP-specific phosphodiesterase inhibitors
WO2001047915A1 (en) 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
JP2005506286A (en) 2001-03-02 2005-03-03 ブリストル−マイヤーズ　スクイブ　カンパニー Combined administration of melanocortin receptor agonist and phosphodiesterase inhibitor for the treatment of cyclic-AMP related diseases
US20030069169A1 (en) 2001-03-02 2003-04-10 Macor John E. Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
WO2002069905A2 (en) 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2004005258A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
WO2004067006A1 (en) 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
GB2406856A (en) 2003-10-07 2005-04-13 Renovis Inc Novel amide compounds as ion channel ligands and uses thereof
WO2006135828A2 (en) 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
Aoki, et al., Effect of a Novel Anti-Inflammatory Compound, YM976, on Antigen-induced Eosinophil Infiltration into the Lungs in Rats, Mice, and Ferrets, The Journal of Pharmacology and Experimental Therapeutics, (2000), vol. 295, No. 3, pp. 1149-1155.
Barneoud, P., et. al, Quantitative Motor Assessment in Fals Mice: A Longitudinal Study, Neuroreport, vol. 8, pp. 2861-2865, (1997).
Berk, C., et al., Thalamic Deep Brain Stimulation for the Treatment of Tremor Due to Multiple Sclerosis: A Prospective Study of Tremor and Quality of Life, J. Neurosurg, vol. 97, pp. 815-320, (2002).
Burnolie, et al., Synthesis, Structure-Activity Relationships, and Pharmacological Profile of 9-Arnino-4-oxo-l-phenyl-3,4,6,7-tetrahydro[1,41diazepino[6,7,1-hi]indoles: Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors, J. Med. Chem., (2000), vol. 43, pp. 4850-4867.
He, et al., Novel Cyclic Compounds as Potent Phosphodiesterase 4 Inhibitors, J. Med. Chem vol. 41, pp. 4216-4223, (1998).
Houslay, et al., Phosphodiesterase-4 as a Therpaeutic Target, DDT, vol. 10, No. 22, (2005), pp. 1503-1519.
International Search Report for WO2008/145840 dated Dec. 4, 2008.
Menniti, et al., Phosphodiesterases in the CNS: Targets for Drug Development, Nature Reviews, vol. 5, (2006), pp. 660-670.
Nikulina, E., et. al., The Phosphodiesterase Inhibitor Rolipram Delivered After a Spinal Cord Lesion Promotes Axonal Regeneration and Functional Recovery, Proceedings of the National Academy of Sciences of the United States of America, vol. 101, No. 23, pp. 8786-8790, (2004).
Robichaud, et al., Emesis Induced by inhibitors of Type IV Cyclic Nucleotide Phosphodiesterase (PDE IV) in the Ferret, Neuropharmacology, vol. 38, (1999), pp. 289-297.
Sawanishi, et al., Selective inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed Purines, J. Med. Chem., (1997), vol. 40, pp. 3248-3253.
U.S. Appl. No. 12/573,226-Office Action Dated Dec. 10, 2010.
U.S. Appl. No. 12/573,226—Office Action Dated Dec. 10, 2010.
U.S. Appl. No. 12/573,322, filed Oct. 5, 2009, Delay-Goyet et al.
U.S. Appl. No. 12/573,322-Office Action Dated Jul. 29, 2010.
U.S. Appl. No. 12/573,322—Office Action Dated Jul. 29, 2010.
U.S. Appl. No. 12/573,326, filed Oct. 5, 2009, Delay-Goyet et al.
U.S. Appl. No. 12/573,326-Office Action Dated Jul. 23, 2010.
U.S. Appl. No. 12/573,326—Office Action Dated Jul. 23, 2010.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393236B2 (en) 2007-04-19 2016-07-19 Sanofi Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxido-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of cranial traumas

Also Published As

Publication number Publication date
JP2010524905A (en) 2010-07-22
FR2915098B1 (en) 2009-06-05
CA2684172C (en) 2015-10-27
TW200911248A (en) 2009-03-16
CY1111779T1 (en) 2015-10-07
AR066106A1 (en) 2009-07-22
KR101470043B1 (en) 2014-12-05
HRP20110459T1 (en) 2011-07-31
CA2684172A1 (en) 2008-12-04
EA015355B1 (en) 2011-06-30
EP2150253A2 (en) 2010-02-10
DE602008005873D1 (en) 2011-05-12
UY31033A1 (en) 2008-11-28
NZ580483A (en) 2011-06-30
EA200970969A1 (en) 2010-02-26
BRPI0810446A2 (en) 2014-10-14
WO2008145840A2 (en) 2008-12-04
CL2008001134A1 (en) 2009-01-16
ME00934B (en) 2012-06-20
ATE503481T1 (en) 2011-04-15
IL201451A0 (en) 2010-05-31
CN101674829B (en) 2012-01-18
FR2915098A1 (en) 2008-10-24
WO2008145840A3 (en) 2009-06-25
SI2150253T1 (en) 2011-07-29
PT2150253E (en) 2011-06-17
KR20090130063A (en) 2009-12-17
ES2363056T3 (en) 2011-07-19
TWI411435B (en) 2013-10-11
MX2009011285A (en) 2009-11-02
AU2008257321B2 (en) 2013-08-15
HK1142000A1 (en) 2010-11-26
IL201451A (en) 2013-04-30
DK2150253T3 (en) 2011-07-25
MY146657A (en) 2012-09-14
PA8776601A1 (en) 2008-11-19
PL2150253T3 (en) 2011-08-31
US20100137370A1 (en) 2010-06-03
JP5386477B2 (en) 2014-01-15
JO2662B1 (en) 2012-06-17
AU2008257321A1 (en) 2008-12-04
CN101674829A (en) 2010-03-17
EP2150253B1 (en) 2011-03-30
MA31369B1 (en) 2010-05-03

Similar Documents

Publication Publication Date Title
EP1031350A1 (en) Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US8592443B2 (en) Use of 4 cyclopropylmethoxy-N-(3,5 dichloro-1 oxido-pyridin-4 yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas
US20100130554A1 (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
US9393236B2 (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxido-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide in the treatment of cranial traumas
HK1142000B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas
HK1141724B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
HK1141725B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament in the treatment of motor disorders related to parkinson's disease

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DELAY-GOYET, PHILIPPE;FERZAZ, BADIA;LOLIVIER, JOCELYNE;SIGNING DATES FROM 20091223 TO 20100121;REEL/FRAME:026180/0856

AS Assignment

Owner name: SANOFI, FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:SANOFI-AVENTIS;REEL/FRAME:028413/0927

Effective date: 20110511

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20211126